From: Targeting endothelial cell metabolism for cardio-protection from the toxicity of antitumor agents
Drug | Research type | Vascular action |
---|---|---|
Doxorubicin, daunorubicin | In vitro | Impairment of NO-dependent function DNA damage, ROS generation, caspases 3 & 7 activation, apoptosis |
Cisplatin | In vitro | Increased expression of ICAM-1, tPA, PAI-1, CRP, ROS |
Paclitaxel, docetaxel | In vitro | Cytoskeleton disruption, impairment of proliferation, migration, prothrombotic effect |
5-fluorouracil | In vitro | Blockade of DNA synthesis; disruption of endothelial layer |
Trastuzumab | Clinical | Impairment of endothelial NO production, ROS generation |
VEGF inhibitors | Clinical | Blockade of VEGF – dependent pro-survival mechanisms in endothelium |
 |  | Impairment of endothelial NO production, vasoconstriction, haemorrhages |